KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gains from Sales and Divestitures: 2009-2018

Historic Gains from Sales and Divestitures for Teva Pharmaceutical Industries (TEVA) over the last 5 years, with Dec 2018 value amounting to $1.6 million.

  • Teva Pharmaceutical Industries' Gains from Sales and Divestitures fell 13.06% to $1.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.6 million, marking a year-over-year decrease of 13.06%. This contributed to the annual value of $1.6 million for FY2018, which is 13.06% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Gains from Sales and Divestitures stood at $1.6 million for Q4 2018, which was down 13.06% from $1.9 million recorded in Q4 2017.
  • Teva Pharmaceutical Industries' 5-year Gains from Sales and Divestitures high stood at $54.0 million for Q3 2016, and its period low was $1.6 million during Q4 2018.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $54.0 million (2017), whereas its average is $41.9 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Gains from Sales and Divestitures grew by 3.85% in 2016 and then plummeted by 96.51% in 2017.
  • Teva Pharmaceutical Industries' Gains from Sales and Divestitures (Quarterly) stood at $50.0 million in 2014, then reached $52.0 million in 2015, then climbed by 3.85% to $54.0 million in 2016, then slumped by 96.51% to $1.9 million in 2017, then fell by 13.06% to $1.6 million in 2018.
  • Its Gains from Sales and Divestitures was $1.6 million in Q4 2018, compared to $1.9 million in Q4 2017 and $54.0 million in Q3 2017.